ARCT
Arcturus Therapeutics Holdings Inc.
Price Chart
Latest Quote
$6.97
+0.08 (+1.16%)
Current Price
| Previous Close | $6.89 |
| Open | $6.89 |
| Day High | $7.03 |
| Day Low | $6.71 |
| Volume | 311,895 |
Stock Information
| Shares Outstanding | 28.42M |
| Total Debt | $23.99M |
| Cash Equivalents | $211.38M |
| Revenue | $54.71M |
| Net Income | $-78.67M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $198.11M |
| EPS (TTM) | $-2.83 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.72M |
| Sales | $54.71M |
| Income | $-78.67M |
| Book/sh | $6.73 |
| Cash/sh | $7.44 |
| Employees | 106 |
Financial Ratios
| Quick Ratio | 6.19 |
| Current Ratio | 6.31 |
| Debt/Eq | 12.54 |
Returns & Margins
| ROA | -19.14% |
| ROE | -37.01% |
| Gross Margin | -80.67% |
| Operating Margin | -1403.74% |
| Profit Margin | -143.80% |
Ownership
| Insider Ownership | 7.99% |
| Institutional Ownership | 80.28% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.75 |
| P/S | 3.62 |
| P/B | 1.04 |
Analyst Data
| Recommendation | none |
| Target Price | $19.89 |
Technical Indicators
| SMA20 | $7.31 |
| SMA50 | $8.06 |
| SMA200 | $9.96 |
| RSI | 48.99 |
| ATR | 0.4414 |
| Shares Float | 26.11M |
| Short Float | 29.45% |
| Short Ratio | 15.20 |
| Volatility | 2.35 |
| Rel Volume | 0.70 |
Performance History
| Week | -4.52% |
| Month | -15.62% |
| Quarter | +4.34% |
| 6 Months | -9.13% |
| YTD | +11.52% |
| Year | -43.97% |
| 3 Years | -75.53% |
| 5 Years | -78.85% |
| 10 Years | -79.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $6.97 | 286,200 |
| 2026-06-11 | $6.97 | 316,400 |
| 2026-06-10 | $6.89 | 316,200 |
| 2026-06-09 | $7.16 | 242,200 |
| 2026-06-08 | $7.12 | 334,600 |
| 2026-06-05 | $7.30 | 412,900 |
| 2026-06-04 | $8.04 | 704,300 |
| 2026-06-03 | $7.60 | 468,900 |
| 2026-06-02 | $7.65 | 466,400 |
| 2026-06-01 | $7.77 | 394,700 |
| 2026-05-29 | $7.92 | 411,100 |
| 2026-05-28 | $7.92 | 298,300 |
| 2026-05-27 | $7.66 | 454,600 |
| 2026-05-26 | $7.21 | 334,600 |
| 2026-05-22 | $7.03 | 266,500 |
| 2026-05-21 | $7.02 | 341,200 |
| 2026-05-20 | $6.82 | 428,000 |
| 2026-05-19 | $6.69 | 544,900 |
| 2026-05-18 | $7.03 | 646,300 |
| 2026-05-15 | $7.47 | 548,300 |
| 2026-05-14 | $7.83 | 522,200 |
| 2026-05-13 | $8.26 | 386,200 |
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
đ° Latest News
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
MarketBeat âĸ 2026-06-05T09:02:17Z
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T21:55:03Z
Arcturus Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T21:39:35Z
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-04-30T22:25:10Z
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Motley Fool âĸ 2026-03-25T15:12:00Z
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
MarketBeat âĸ 2026-03-23T18:47:57Z
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
Motley Fool âĸ 2026-03-23T11:27:00Z
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
MarketBeat âĸ 2026-03-12T06:02:14Z
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-05T01:02:25Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $67,221,000 | $138,389,000 | $157,748,000 | $205,755,000 |
| Operating Revenue | $67,221,000 | $138,389,000 | $157,748,000 | $205,755,000 |
| Expenses | ||||
| Interest Expense | $9,000 | $0 | $768,000 | $3,001,000 |
| Total Expenses | $143,481,000 | $234,058,000 | $235,953,000 | $193,578,000 |
| Other Income Expense | $382,000 | $-471,000 | $33,724,000 | $-1,113,000 |
| Net Non Operating Interest Income Expense | $10,095,000 | $15,195,000 | $16,591,000 | $-420,000 |
| Interest Expense Non Operating | $9,000 | $0 | $768,000 | $3,001,000 |
| Operating Expense | $143,481,000 | $234,058,000 | $235,953,000 | $193,578,000 |
| Other Operating Expenses | $-14,810,000 | $-13,921,000 | $-9,051,000 | $-244,000 |
| General And Administrative Expense | $46,079,000 | $52,823,000 | $52,871,000 | $46,071,000 |
| Total Other Finance Cost | - | - | $1,000 | $420,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-65,783,000 | $-80,941,000 | $-29,725,000 | $9,349,000 |
| Net Interest Income | $10,095,000 | $15,195,000 | $16,591,000 | $-420,000 |
| Interest Income | $10,104,000 | $15,195,000 | $17,359,000 | $2,581,000 |
| Normalized Income | $-66,165,000 | $-80,470,000 | $-56,366,960 | $9,874,244 |
| Net Income From Continuing And Discontinued Operation | $-65,783,000 | $-80,941,000 | $-29,725,000 | $9,349,000 |
| Total Operating Income As Reported | $-76,260,000 | $-95,669,000 | $-78,205,000 | $12,177,000 |
| Net Income Common Stockholders | $-65,783,000 | $-80,941,000 | $-29,725,000 | $9,349,000 |
| Net Income | $-65,783,000 | $-80,941,000 | $-29,725,000 | $9,349,000 |
| Net Income Including Noncontrolling Interests | $-65,783,000 | $-80,941,000 | $-29,725,000 | $9,349,000 |
| Net Income Continuous Operations | $-65,783,000 | $-80,941,000 | $-29,725,000 | $9,349,000 |
| Pretax Income | $-65,783,000 | $-80,945,000 | $-27,890,000 | $10,644,000 |
| Special Income Charges | $0 | $0 | $33,953,000 | $0 |
| Interest Income Non Operating | $10,104,000 | $15,195,000 | $17,359,000 | $2,581,000 |
| Operating Income | $-76,260,000 | $-95,669,000 | $-78,205,000 | $12,177,000 |
| Earnings From Equity Interest | - | $0 | $0 | $-515,000 |
| Per Share | ||||
| Diluted EPS | $-2.40 | $-3.00 | $-1.00 | $0.35 |
| Basic EPS | $-2.40 | $-3.00 | $-1.00 | $0.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $7,082,040 | $-72,756 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-63,131,000 | $-76,930,000 | $-57,889,000 | $14,302,000 |
| Total Unusual Items | $382,000 | $-471,000 | $33,724,000 | $-598,000 |
| Total Unusual Items Excluding Goodwill | $382,000 | $-471,000 | $33,724,000 | $-598,000 |
| Reconciled Depreciation | $3,025,000 | $3,544,000 | $2,957,000 | $1,527,000 |
| EBITDA (Bullshit earnings) | $-62,749,000 | $-77,401,000 | $-24,165,000 | $13,704,000 |
| EBIT | $-65,774,000 | $-80,945,000 | $-27,122,000 | $12,177,000 |
| Diluted Average Shares | $27,386,000 | $27,000,000 | $26,628,000 | $27,093,000 |
| Basic Average Shares | $27,386,000 | $27,000,000 | $26,628,000 | $26,445,000 |
| Diluted NI Availto Com Stockholders | $-65,783,000 | $-80,941,000 | $-29,725,000 | $9,349,000 |
| Tax Provision | $0 | $-4,000 | $1,835,000 | $1,295,000 |
| Gain On Sale Of Security | $382,000 | $-471,000 | $-229,000 | $-598,000 |
| Research And Development | $112,212,000 | $195,156,000 | $192,133,000 | $147,751,000 |
| Selling General And Administration | $46,079,000 | $52,823,000 | $52,871,000 | $46,071,000 |
| Other Gand A | $46,079,000 | $52,823,000 | $52,871,000 | $46,071,000 |
| Other Special Charges | - | - | $-33,953,000 | - |
Fetched: 2026-06-12
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $213,985,000 | $240,978,000 | $278,513,000 | $270,312,000 |
| Total Assets | $271,148,000 | $344,069,000 | $429,402,000 | $450,387,000 |
| Total Non Current Assets | $29,702,000 | $38,090,000 | $42,812,000 | $47,054,000 |
| Other Non Current Assets | $1,885,000 | $1,885,000 | $1,885,000 | $2,094,000 |
| Current Assets | $241,446,000 | $305,979,000 | $386,590,000 | $403,333,000 |
| Other Current Assets | $4,973,000 | $9,977,000 | $7,521,000 | $8,686,000 |
| Restricted Cash | $0 | $55,000,000 | $55,000,000 | $0 |
| Receivables | $5,564,000 | $3,974,000 | $32,064,000 | $2,764,000 |
| Accounts Receivable | $5,564,000 | $3,974,000 | $32,064,000 | $2,764,000 |
| Cash Cash Equivalents And Short Term Investments | $230,909,000 | $237,028,000 | $292,005,000 | $391,883,000 |
| Cash And Cash Equivalents | $230,909,000 | $237,028,000 | $292,005,000 | $391,883,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $24,998,000 | $28,550,000 | $30,216,000 | $94,755,000 |
| Long Term Debt And Capital Lease Obligation | $20,784,000 | $24,998,000 | $25,907,000 | $30,216,000 |
| Current Debt And Capital Lease Obligation | $4,214,000 | $3,552,000 | $4,309,000 | $64,539,000 |
| Current Debt | - | - | - | $60,655,000 |
| Other Current Borrowings | - | - | - | $60,655,000 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $57,163,000 | $103,091,000 | $150,889,000 | $180,075,000 |
| Total Non Current Liabilities Net Minority Interest | $20,784,000 | $37,602,000 | $68,900,000 | $53,091,000 |
| Non Current Deferred Liabilities | $0 | $12,604,000 | $42,496,000 | $20,071,000 |
| Current Liabilities | $36,379,000 | $65,489,000 | $81,989,000 | $126,984,000 |
| Current Deferred Liabilities | $8,246,000 | $21,935,000 | $47,343,000 | $36,116,000 |
| Payables And Accrued Expenses | $16,971,000 | $26,697,000 | $24,419,000 | $22,291,000 |
| Payables | $4,235,000 | $7,194,000 | $5,920,000 | $8,744,000 |
| Accounts Payable | $4,235,000 | $7,194,000 | $5,279,000 | $7,449,000 |
| Total Tax Payable | - | $0 | $641,000 | $1,295,000 |
| Income Tax Payable | - | $0 | $641,000 | $1,295,000 |
| Other Non Current Liabilities | - | - | $497,000 | $2,804,000 |
| Equity | ||||
| Common Stock Equity | $213,985,000 | $240,978,000 | $278,513,000 | $270,312,000 |
| Total Equity Gross Minority Interest | $213,985,000 | $240,978,000 | $278,513,000 | $270,312,000 |
| Stockholders Equity | $213,985,000 | $240,978,000 | $278,513,000 | $270,312,000 |
| Retained Earnings | $-514,590,000 | $-448,807,000 | $-367,866,000 | $-338,141,000 |
| Long Term Equity Investment | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $28,414,279 | $27,000,000 | $26,828,000 | $26,555,000 |
| Share Issued | $28,414,279 | $27,000,000 | $26,828,000 | $26,555,000 |
| Tangible Book Value | $213,985,000 | $240,978,000 | $278,513,000 | $270,312,000 |
| Invested Capital | $213,985,000 | $240,978,000 | $278,513,000 | $330,967,000 |
| Working Capital | $205,067,000 | $240,490,000 | $304,601,000 | $276,349,000 |
| Capital Lease Obligations | $24,998,000 | $28,550,000 | $30,216,000 | $34,100,000 |
| Total Capitalization | $213,985,000 | $240,978,000 | $278,513,000 | $270,312,000 |
| Additional Paid In Capital | $728,547,000 | $689,758,000 | $646,352,000 | $608,426,000 |
| Capital Stock | $28,000 | $27,000 | $27,000 | $27,000 |
| Common Stock | $28,000 | $27,000 | $27,000 | $27,000 |
| Non Current Deferred Revenue | $0 | $12,604,000 | $42,496,000 | $20,071,000 |
| Long Term Capital Lease Obligation | $20,784,000 | $24,998,000 | $25,907,000 | $30,216,000 |
| Current Deferred Revenue | $8,246,000 | $21,935,000 | $47,343,000 | $36,116,000 |
| Current Capital Lease Obligation | $4,214,000 | $3,552,000 | $4,309,000 | $3,884,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,948,000 | $13,305,000 | $5,918,000 | $4,038,000 |
| Current Accrued Expenses | $12,736,000 | $19,503,000 | $18,499,000 | $13,547,000 |
| Net PPE | $27,817,000 | $36,205,000 | $40,927,000 | $44,960,000 |
| Accumulated Depreciation | $-12,491,000 | $-11,811,000 | $-8,740,000 | $-5,783,000 |
| Gross PPE | $40,308,000 | $48,016,000 | $49,667,000 | $50,743,000 |
| Leases | $2,612,000 | $2,644,000 | $2,655,000 | $2,491,000 |
| Other Properties | $36,023,000 | $43,538,000 | $44,546,000 | $42,796,000 |
| Machinery Furniture Equipment | $1,673,000 | $1,834,000 | $2,233,000 | $2,112,000 |
| Properties | $0 | $0 | $0 | $0 |
| Construction In Progress | - | $0 | $233,000 | $3,344,000 |
| Investments And Advances | - | - | - | $0 |
Fetched: 2026-06-12
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-74,501,000 | $-60,395,000 | $-21,000,000 | $24,267,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-74,271,000 | $-59,747,000 | $-18,099,000 | $31,993,000 |
| Cash Flow From Continuing Operating Activities | $-74,271,000 | $-59,747,000 | $-18,099,000 | $31,993,000 |
| Operating Gains Losses | $382,000 | $471,000 | $-33,863,000 | $890,000 |
| Investing Activities | ||||
| Capital Expenditure | $-230,000 | $-648,000 | $-2,901,000 | $-7,726,000 |
| Investing Cash Flow | $-230,000 | $-648,000 | $-2,901,000 | $-7,726,000 |
| Cash Flow From Continuing Investing Activities | $-230,000 | $-648,000 | $-2,901,000 | $-7,726,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $12,273,000 | $682,000 | $609,000 | $411,000 |
| Financing Cash Flow | $13,382,000 | $5,418,000 | $-24,087,000 | $-2,859,000 |
| Cash Flow From Continuing Financing Activities | $13,382,000 | $5,418,000 | $-24,087,000 | $-2,859,000 |
| Net Common Stock Issuance | $12,273,000 | $682,000 | $609,000 | $411,000 |
| Common Stock Issuance | $12,273,000 | $682,000 | $609,000 | $411,000 |
| Other | ||||
| Repayment Of Debt | $-15,000,000 | $0 | $-47,364,000 | $-5,000,000 |
| Issuance Of Debt | $15,000,000 | $0 | $20,000,000 | $0 |
| Interest Paid Supplemental Data | $0 | $0 | $2,127,000 | $813,000 |
| Income Tax Paid Supplemental Data | $0 | $1,407,000 | $0 | $0 |
| End Cash Position | $232,794,000 | $293,913,000 | $348,890,000 | $393,977,000 |
| Beginning Cash Position | $293,913,000 | $348,890,000 | $393,977,000 | $372,569,000 |
| Changes In Cash | $-61,119,000 | $-54,977,000 | $-45,087,000 | $21,408,000 |
| Proceeds From Stock Option Exercised | $1,109,000 | $4,736,000 | $2,668,000 | $1,730,000 |
| Net Issuance Payments Of Debt | $0 | $0 | $-27,364,000 | $-5,000,000 |
| Net Long Term Debt Issuance | $0 | $0 | $-27,364,000 | $-5,000,000 |
| Long Term Debt Payments | $-15,000,000 | $0 | $-47,364,000 | $-5,000,000 |
| Long Term Debt Issuance | $15,000,000 | $0 | $20,000,000 | $0 |
| Net PPE Purchase And Sale | $-230,000 | $-648,000 | $-2,901,000 | $-7,726,000 |
| Purchase Of PPE | $-230,000 | $-648,000 | $-2,901,000 | $-7,726,000 |
| Change In Working Capital | $-39,200,000 | $-20,809,000 | $7,381,000 | $-12,557,000 |
| Change In Other Working Capital | $-23,872,000 | $-55,207,000 | $38,606,000 | $-14,694,000 |
| Change In Other Current Liabilities | $-4,214,000 | $-3,645,000 | $-4,309,000 | $-4,477,000 |
| Change In Other Current Assets | $3,696,000 | $4,562,000 | $4,045,000 | $3,264,000 |
| Change In Payables And Accrued Expense | $-18,224,000 | $7,847,000 | $-2,826,000 | $6,331,000 |
| Change In Accrued Expense | $-15,265,000 | $5,932,000 | $-588,000 | $9,443,000 |
| Change In Payable | $-2,959,000 | $1,915,000 | $-2,238,000 | $-3,112,000 |
| Change In Account Payable | $-2,959,000 | $1,915,000 | $-2,238,000 | $-3,112,000 |
| Change In Prepaid Assets | $5,004,000 | $-2,456,000 | $1,165,000 | $-3,584,000 |
| Change In Receivables | $-1,590,000 | $28,090,000 | $-29,300,000 | $603,000 |
| Changes In Account Receivables | $-1,590,000 | $28,090,000 | $-29,300,000 | $603,000 |
| Stock Based Compensation | $25,408,000 | $37,988,000 | $34,649,000 | $30,611,000 |
| Asset Impairment Charge | $1,897,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $3,025,000 | $3,544,000 | $2,957,000 | $1,527,000 |
| Depreciation And Amortization | $3,025,000 | $3,544,000 | $2,957,000 | $1,527,000 |
| Net Foreign Currency Exchange Gain Loss | $382,000 | $471,000 | $90,000 | $375,000 |
| Net Income From Continuing Operations | $-65,783,000 | $-80,941,000 | $-29,725,000 | $9,349,000 |
| Earnings Losses From Equity Investments | - | $0 | $0 | $515,000 |
| Other Non Cash Items | - | - | $502,000 | $2,173,000 |
| Depreciation | - | - | - | $1,527,000 |
Fetched: 2026-06-12